MedPath

Comparison of Nasal Positive End Expiratory Pressure Valve to Dental Device as an Alternative Treatment for Obstructive Sleep Apnea

Not Applicable
Completed
Conditions
Obstructive Sleep Apnea
Adverse Effects
Interventions
Device: nasal peep valve "Provent"
Registration Number
NCT01553383
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

Determine the clinical efficacy in terms of Apnea Hypopnea Index (AHI), excessive daytime sleepiness (EDS), nocturnal oxygenation of a nasal Positive end-expiratory pressure (PEEP) valve "Provent" in obstructive sleep apnea. The hypothesis is the efficacy will be better than dental device.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Symptomatic patients confirmed of OSA by sleep study (PSG according to AASM criteria or validated level 3 portable monitoring devices with AHI > 10/hr)
  • Not using CPAP for any reasons or patients on dental device but would like to try alternative treatments for OSA.
  • Able to sign informed consent and use the PEEP nasal valve.
  • Age between 18-65 years old.
  • Willing to attend follow up.
Read More
Exclusion Criteria
  • Known nasal problems like deformities or significant rhinitis affecting application of PEEP nasal valve.
  • Unable to sign consent or use PEEP nasal valve.
  • Significant or unstable co-morbidities requiring other forms of treatment for OSA as priority.
  • Coexisting sleep disordered breathing condition other than OSA requiring more complex treatment. E.g. central sleep apnea, significant Cheyne Stokes respiration or hypoventilation syndrome.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Dental devicenasal peep valve "Provent""Provent" nasal peep valve vs dental device
CPAPnasal peep valve "Provent"continuous positive airway pressure "CPAP" vs nasap peep valve "Provent"
Primary Outcome Measures
NameTimeMethod
Apnea Hypopnea Index (AHI)1 month
Secondary Outcome Measures
NameTimeMethod
side effects as a measure of tolerability1 month

Trial Locations

Locations (1)

Department of Medicine and Therapeutics, Prince of Wales Hospital, CUHK

🇭🇰

Shatin, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath